Application of indinavir and/or derivatives thereof in preparation of antituberculous drugs

The invention provides application of indinavir and/or derivatives thereof in preparation of antituberculosis drugs, and relates to the technical field of medicines. Indinavir is an anti-reverse transcriptase inhibitor and can be combined with an HIV protease catalytic site to inhibit division of a virus polyprotein precursor into a mature functional protein required by virus replication. Indinavir can be used in cooperation with other anti-retroviral agents to treat HIV infection; the application finds that the indinavir has an effect of inhibiting intracellular survival of mycobacterium tuberculosis at a macrophage level, that is, the indinavir has a potential as an antituberculosis drug, and has an important application value in clinical treatment of HIV combined MTB infection..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 30. Jan. Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

GUO QINGLONG [VerfasserIn]
BI JING [VerfasserIn]
ZHANG GUOLIANG [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-01-30, Last update posted on www.tib.eu: 2024-04-08, Last updated: 2024-04-15

Patentnummer:

CN117462551

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA002709074